Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

NCT07121829 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

44

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Melanoma
Solid Tumor
Pilocytic Astrocytoma
Non Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
MAP Kinase Family Gene Mutation
RAS Mutation
RAF Mutation
MEK Mutation

Interventions

DRUG: Tovorafenib
DRUG: Tovorafenib Drug: Pimasertib

Sponsor

Day One Biopharmaceuticals, Inc.